RxDoctor Payments Data

Amy van Dorfy, MD

Family Medicine · Marble Falls, TXNPI 1578535787

Payments from drug & device makers

$3,634in general payments, 2019–2025

Across 150 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$652
  • Medtronic$519
  • Lilly USA, LLC$315
  • Novo Nordisk$210
  • Harmony Biosciences LLC$206
  • Globus Medical$175
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,59499%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,634 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,743
Medicare patients
127
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$74,233
MyrbetriqMirabegron63$47,066
TrulicityDulaglutide29$32,207
JardianceEmpagliflozin29$25,449
OzempicSemaglutide24$21,821
WegovySemaglutide14$20,219
EliquisApixaban28$20,160
Repatha SureclickEvolocumab21$11,543
BelsomraSuvorexant18$8,136
PremarinEstrogens, Conjugated11$4,756
SynthroidLevothyroxine Sodium30$3,273
Atorvastatin Calcium203$2,585
Montelukast Sodium160$2,221
Duloxetine Hcl85$2,040
Pregabalin46$1,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$315$106,440101 claims
Astellas Pharma US IncMyrbetriq$112$47,06663 claims
Novo NordiskOzempic, Wegovy$210$42,04138 claims
Boehringer IngelheimJardiance$23$25,44929 claims
PfizerEliquis, Premarin$95$24,91639 claims
MerckBelsomra$39$8,13618 claims
AbbVieSynthroid$60$3,27330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Marble Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →